Photo courtesy Jezper/Shutterstock.com
Collaborations between popular consumer genetic testing companies like 23andMe and pharmaceutical giants like GlaxoSmithKline to develop new drugs raise data privacy concerns for in-house lawyers, who must navigate this murky compliance landscape largely through privacy policies.
March 05, 2019 at 01:00 AM
1 minute read
The original version of this story was published on Corpcounsel/corpcounsel
Seeking insight into ancestral backgrounds or clues into various health risks have led millions to direct-to-consumer genetic tests.
The market for such private genetic testing is expected to grow to $310 million by 2022, up from $99 million in 2017, according to researcher Kalorama Information.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
